FGF23 and X-linked hypophosphatemia: In contrast to this conventional therapy, the recently licensed anti-FGF23 antibody treatment, burosumab, targets the underlying pathophysiology of XLH by inhibiting and blocking the effects of FGF23, which restores phosphate homeostasis [15–18].